// App-Quantinova.ai

983 : Hepatitis C (HCV) in Patients Without Fibrosis or with Minimal Fibrosis: The Impact of Treatment and Sustained Virologic Response (SVR) on Patient‐Reported Outcomes (PROs)

Researchers

Presenter

  • Zobair M. Younossi

Principal Investigators

  • Maria Stepanova

  • Tarik Asselah

  • Graham R. Foster

  • Keyur Patel

  • Norbert Bru

  • Mark G. Swain

  • Tram T. Tran

  • Rafael Esteban

  • Massimo Colombo

  • Stephen Pianko

  • Linda Henry

  • Marc Bourliere

Medical Centers

  • Center for Liver Disease, Department of Medicine, Inova Fairfax Hospital, Falls church, Virginia, United States

  • Center for Outcomes Research in Liver Disease, Washington DC, VA

  • Hopital Beaujon, Clichy, France

  • Queen Mary University of London, London, United Kingdom

  • Renal Section, James J Peter Veterans Affairs Medical Center, New York, NY

  • Universitat Autonoma de Barcelona-Spain, Barcelona, Spain

  • Humanitas Clinical and Research Center, Rozzano, Italy

  • Hopital Saint Joseph, Marseille, France

  • Toronto Center for Liver Diseases, Toronto, ON, Canada

  • Internal Medicine, University of Calgary, Calgary, AB, Canada

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • Department of Rheumatology, Monash Medical Centre, Melbourne, Australia

Locations

  • United States

  • France

  • United Kingdom

  • Spain

  • Italy

  • Canada

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Hepatitis C

Biomarkers

  • Sustained virological response

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved